wegovy

Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk A/S (NYSE:NVO), weight-loss drug Ozempic and talk show host Oprah Winfrey. What Retail Is Saying: Retail investors in subreddit r/StockMarket are pointing to the connection between Novo Nordisk...

Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X (formerly Twitter) to share his thoughts on the potential financial benefits of using Ozempic, a weight-loss drug developed by Novo Nordisk A/S (NYSE:NVO...

In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time special that delves into the stigma associated with weight loss drugs like Ozempic and Wegovy. What Happened: Winfrey dedicated a prime-time special to...

Goldman Sachs analysts are identifying a substantial opportunity in the manufacturing sector for new obesity therapeutics as demand escalates for these treatments. Goldman Sachs projects the global obesity market to potentially reach $100 billion by 2030, with a more optimistic outlook suggesting...

The Centers for Medicare and Medicaid Services (CMS) is considering the inclusion of Novo Nordisk’s (NYSE:NVO) obesity drug Wegovy in its coverage for heart disease patients with obesity. What Happened: The CMS is reviewing the FDA's action to expand the use of Wegovy to reduce the risk of...

Novo Nordisk A/S (NYSE:NVO)’s Wegovy garnered the Food and Drug Administration’s approval for expanded use Friday, marking what the drugmaker said is a pivotal turn in the treatment landscape for individuals grappling with the dual challenges of obesity and established cardiovascular...

A recent study by the Pew Research Center has shown that a majority of Americans are doubtful about the potential of new weight loss drugs, such as Ozempic and Wegovy, to impact the country’s obesity rate significantly. What Happened: Despite the optimism surrounding these drugs, the majority...

The race for new drugs to fight obesity and associated diabetes and cardiovascular diseases heated up on Monday after positive results from trials by Zealand Pharma were published, pushing the Danish company’s shares 30% higher. Zealand Pharma’s survodutide drug showed positive results...

The introduction of Novo Nordisk A/S‘s (NYSE:NVO) groundbreaking weight-loss treatments Wegovy and Ozempic are sending ripples through the food industry. CEOs from across industries are seeking insights from Novo Nordisk, indicating a widespread concern about the potential shifts in consumer...

Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition is part of a larger deal where Novo Holdings is set to acquire Catalent, Inc. (NYSE:CTLT...

Eli Lilly (NYSE:LLY) reports its fourth quarter earnings next week and, as Novo Nordisk (NYSE:NVO) did on Wednesday, is expected to wow investors with earnings and revenue beats thanks, in large part, to the overwhelming success of its diabetes treatments that have become popular weight-loss...

Novo Nordisk (NYSE:NVO) has reported a remarkable increase in its market value, reaching $500 billion, driven by a surge in demand for its key drugs. What Happened: The Danish pharmaceutical company’s market value soared to $506 billion on Wednesday following the release of its 2023 earnings...

Former President Donald Trump‘s recent weight loss has been attributed to healthier eating habits and the absence of buffet visits at his Mar-a-Lago club, with his wife Melania Trump reportedly playing a key role. What Happened: A source told Page Six that Trump,...

Deutsche Bank has recently conducted a survey suggesting that patients using Novo Nordisk A/S (NYSE:NVO) weight loss medication, Ozempic, may increase their caloric intake after discontinuing the treatment. What Happened: The survey involved 600 U.S. consumers. Seventy percent of the participants ...

Novo Nordisk A/S (NYSE:NVO), the maker of ‘Miracle‘ weight loss drugs Ozempic and Wegovy, is reportedly set to construct a large-scale manufacturing facility in Dublin as demand surges for its weight-loss drugs. What Happened: The pharmaceutical giant from Denmark has put forth plans...